Genedrive MT-RNR1 ID Kit to detect genetic variation and protect hearing in babies: early value appraisal.
The Genedrive MT-RNR1 ID Kit has potential benefits in identifying babies at risk of hearing loss from aminoglycoside due to the MT-RNR1 m.1555A>G variant, allowing for alternative antibiotics to be used instead. However, managing the risk of early access is important, including ensuring timely antibiotics, avoiding unnecessary use of alternative antibiotics, and confirming positive results. The economic evidence suggests cost-effectiveness, but upfront costs may be high. Data should be generated in centers with babies from different ethnicities to promote equality.
Recent Posts
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before Phase 3
Early HEOR Market Access Integration
In this brief interview on ISPOR, Indranil Bagchi asserts that HEOR market access integration must occur earlier in drug development—ideally before Ph...
Addressing AI Polyp Detection Gaps: A Roadmap for Evidence Generation and NHS Integration
Addressing Evidence Gaps in AI Polyp Detection
AI Polyp Detection Gaps persist in colorectal cancer screening, as highlighted by the National Institute for He...
Health Investment Returns: Harnessing Health as a Strategic Economic Asset
Health as a Strategic Economic Imperative
A country's enduring strength stems not solely from military or industrial resources but from the vitality and productivity of its populace. A recent EFPIA Guest Blog by Michael Oberreiter frames he...